Global
Global Home
|
CSL Behring US
|
CSL Plasma
|
All CSL Behring Web Sites
Include All CSL Behring Country Sites
Choose country
Austria
Belgium/Luxembourg
Brazil
Canada
China
Denmark
France
Germany
Italy
Japan
Mexico
Netherlands
Nordic
Spain
Switzerland
UK
USA
CSL Plasma US
CSL Plasma Germany
Home
About CSL Behring
Products
Bleeding Disorders
Fluid Replacement Therapy
Hereditary Angioedema (HAE)
Immunoglobulins
Immunodeficiencies
Pulmonary
Wound Healing
Patient Commitment
Quality & Safety
CSL Research & Development
Clinical Trials
Other Areas of Business
News Room
Knowledge Center
Careers
Home
> Products
> Immunoglobulins
> Resources
Immunoglobulins
About Our Therapies
Product List
Resources
> View product pipeline
> Subscribe to news feed
News
National Jewish Health Names Recipient of The CSL Behring/National Jewish Health Fellowship in Immunology
CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research into Neuroimmunology
Feature: Stress-Relieving Tips for Families Living with a
Rare Disease
2011 Interlaken Leadership Awards
Study demonstrates relationship between subcutaneous IgG (SCIg) dosage and clinical outcomes with Hizentra® treatment in patients with primary immunodeficiencies
New Model Provides Insights into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients with Primary Immunodeficiencies
Hizentra Receives European Commission Approval
When Is a Cold Not Just a Cold
PID Awareness
Bern IG Manufacturing Facility Receives FDA Approval
Personal Stories
Carl's Story
Lynne S.'s Story
Lynne D.'s Story
Eric's Story
Jean's Story
Ted's Story
Thought Leadership
Key Issues Dialogue:
PID & Neurological Disorders
Key Issues Dialogue:
The Partnership between the Modell Foundation & CSL Behring
Key Issues Dialogue:
HAE & PID
Key Issues Dialogue:
ITP
Products
Hizentra® (US)
Privigen® (Germany)
Privigen® (US)
Rhophylac® (US)
Cytogam® (US)